Pelthos Therapeutics Inc. (PTHS) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Pelthos Therapeutics Inc. (PTHS) closed at USD 20.26 on 2026-10-15, a change of -37.7 % over the past year, with a market capitalization of USD 77.14M.

Pelthos Therapeutics Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Pelthos Therapeutics Inc. key figures

Previous close

USD 20.26 (2026-10-15)

1-year change

-37.7 %

Market cap

USD 77.14M

Enterprise value

USD 126.06M

P/E ratio (trailing)

-0.73

P/E ratio (forward)

-3.55

EPS (trailing)

-27.53

EPS (forward)

-5.68

PEG ratio

n/a

Price to book

-49.88

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

2.89

Employees

92

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Pelthos Therapeutics Inc.

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Pelthos Therapeutics Inc. and compare it with other stocks.